Malkon G. Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Malkon G. Sanchez has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Behzad M. Toosi
Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, Canada
74 shared publications - Franco J. Vizeacoumar
Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
74 shared publications - Jessica C. Sharpe
Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, Canada
74 shared publications - Aaron P. White
University of Saskatchewan
73 shared publications - Amr El Zawily
Department of Plant and Microbiology, Faculty of Science, Damanhour University, Damanhour 22511, Egypt
73 shared publications - Andrew Freywald
University of Saskatchewan
73 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S6: Hits from the EPHA2 BioID assay.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S6: Hits from the EPHA2 BioID assay.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precision-recall curves after applying BAGELalgorithm to the screening data. F measure provided in the inset represents the harmonic mean ofprecision & recall of the screen.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precision-recall curves after applying BAGELalgorithm to the screening data. F measure provided in the inset represents the harmonic mean ofprecision & recall of the screen.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S7: GO analysis of the BioID assay.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S7: GO analysis of the BioID assay.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the differentially expressedphosphorylated proteins data produced by GSEA software used to generate the heatmap in A.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Fig. S2. A. Heatmap of the differentially expressed phosphorylated proteins that are enriched inthe top 15 gene ontology (GO) processes generated using GSEA software. B. Gene SetEnrichment Analysis plots of the top 15 GO processes for the differentially expressedphosphorylated proteins data produced by GSEA software used to generate the heatmap in A.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S2: Protein phosphorylation events distinct in αEPHA2-Cond and cIgG-Tr cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S2: Protein phosphorylation events distinct in αEPHA2-Cond and cIgG-Tr cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S5: GO analysis of the shRNA screen in αEPHA2-Cond cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S5: GO analysis of the shRNA screen in αEPHA2-Cond cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S1: Phosphorylated proteins expressed differently in αEPHA2-Cond and cIgG-Tr cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Table S1: Phosphorylated proteins expressed differently in αEPHA2-Cond and cIgG-Tr cells.